S
42.76
-0.04 (-0.09%)
| Penutupan Terdahulu | 42.80 |
| Buka | 42.33 |
| Jumlah Dagangan | 1,174,461 |
| Purata Dagangan (3B) | 2,122,566 |
| Modal Pasaran | 4,361,838,592 |
| Harga / Jualan (P/S) | 13.14 |
| Harga / Buku (P/B) | 18.32 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Nov 2025 |
| EPS Cair (TTM) | -2.55 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 20.22% |
| Nisbah Semasa (MRQ) | 10.25 |
| Aliran Tunai Operasi (OCF TTM) | -229.84 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -134.32 M |
| Pulangan Atas Aset (ROA TTM) | -50.15% |
| Pulangan Atas Ekuiti (ROE TTM) | -106.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Scholar Rock Holding Corporatio | Menaik | Menaik |
AISkor Stockmoo
-0.7
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.70 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 4.35% |
| % Dimiliki oleh Institusi | 118.63% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (UBS, 40.32%) | Beli |
| Median | 53.50 (25.12%) | |
| Rendah | 42.00 (Wolfe Research, -1.78%) | Beli |
| Purata | 52.33 (22.38%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 42.49 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 26 Jan 2026 | 58.00 (35.64%) | Beli | 44.89 |
| Citigroup | 09 Jan 2026 | 55.00 (28.62%) | Beli | 42.18 |
| UBS | 07 Jan 2026 | 60.00 (40.32%) | Beli | 44.23 |
| Barclays | 17 Dec 2025 | 52.00 (21.61%) | Beli | 44.01 |
| 17 Nov 2025 | 45.00 (5.24%) | Beli | 36.47 | |
| JP Morgan | 18 Nov 2025 | 47.00 (9.92%) | Beli | 39.81 |
| Wolfe Research | 18 Nov 2025 | 42.00 (-1.78%) | Beli | 39.81 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HO JUNLIN | - | 44.97 | -8,016 | -360,480 |
| MARANTZ JING L. | - | 44.97 | -5,798 | -260,736 |
| PARLAVECCHIO CARYN | - | 44.97 | -6,600 | -296,802 |
| QATANANI MO | - | 46.37 | -23,304 | -1,089,546 |
| Jumlah Keseluruhan Kuantiti Bersih | -43,718 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,007,564 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 45.53 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| QATANANI MO | Pegawai | 22 Jan 2026 | Jual automatik (-) | 14,898 | 47.76 | 711,528 |
| HO JUNLIN | Pegawai | 16 Jan 2026 | Jual (-) | 8,016 | 44.97 | 360,480 |
| MARANTZ JING L. | Pegawai | 16 Jan 2026 | Jual (-) | 5,798 | 44.97 | 260,736 |
| PARLAVECCHIO CARYN | Pegawai | 16 Jan 2026 | Jual (-) | 6,600 | 44.97 | 296,802 |
| QATANANI MO | Pegawai | 16 Jan 2026 | Jual (-) | 8,406 | 44.97 | 378,018 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Jan 2026 | Pengumuman | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 12 Jan 2026 | Pengumuman | Scholar Rock Highlights 2026 Strategic Priorities |
| 05 Jan 2026 | Pengumuman | Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 13 Dec 2025 | Pengumuman | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 18 Nov 2025 | Pengumuman | Scholar Rock to Present at Upcoming Investor Conferences |
| 14 Nov 2025 | Pengumuman | Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights |
| 12 Nov 2025 | Pengumuman | Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 04 Nov 2025 | Pengumuman | Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |